Table 2

Carcinogenicity of estrogens, catechol estrogens, and quinones in B6C3F1 male mice

CompoundDose nmol/g body weightEffective no. of animalsTotal no. of tumors/TBATBA, %Liver tumors No. of mice with other neoplasms
Total no. of tumors/TBATBA, %Carcinomas/TBATBA, %Adenomas/TBATBA, %
E230206/6305/5253/3152/2101A
2-OHE2302813/103610/9325/4145/5181B, 1C, 1D
4-OHE2302415/104213/8336/5217/3122A
E22,3-Q7.52610/831108316/5194/312
E2-3,4-Q7.5215/4195/4194/3141/15
E130324/393/26*003/261A
2-OHE1303011/9309/7234/4135/4131B, 1E
4-OHE130338/8246/6185/5152/261A
E12,3-Q7.52517/124814/114412/9362/282A
E1-3,4-Q3.71013/66013/66013/660§0
BP601274/1210068/1210055/119213/7584B, 1F
Solvent1911/7379/5265/4214/2102A
Untreated3311/11338/8246/6182/263A
  • Effective number of animals, number of mice that survived after weaning; TBA, tumor-bearing animals; A, lung adenoma; B, lung carcinoma; C, eye papillary carcinoma (sebaceous); D, pancreatic lymph node lymphoma; E, spleen lymphoma; F, malignant lymphoma; BP, benzo[a]pyrene. 

  • * The mice treated with E1 had significantly fewer tumors than the untreated mice (P = 0.046). 

  • E1 was significantly less carcinogenic than the solvent (P < 0.016) and no treatment (P < 0.013). 

  • E1-3,4-Q was significantly more tumorigenic than no treatment (P < 0.044). 

  • § E1-3,4-Q was significantly more carcinogenic than the solvent (P < 0.047). 

  • E1-3,4-Q vs. BP does not approach the nominal 0.05 P value of the level of significance.